Compare CVS Health Corp (CVS) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Jumia Technologies AG - ADR — how do they compare? CVS Health Corp trades at $86.1 (market cap $112.29B), while Jumia Technologies AG - ADR trades at $6.53 (market cap $865.90M). The key difference: CVS Health Corp is far larger — about 129.7× Jumia Technologies AG - ADR's market cap, and CVS Health Corp pays a 3.03% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Jumia Technologies AG - ADR for 28 Days on average.
| CVS | JMIA | |
|---|---|---|
Market Cap | $112.29B | $865.90M |
Volume | 7,763,676 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $14.60 |
52-Week Low | $70.08 | $5.69 |
Typical Hold Time | 83 Days | 28 Days |
Enterprise Value | $174.64B | $831.54M |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
JMIA trades at $6.74, down 0.88% with bearish technical signals. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses (-$62M net income). Recent $50M capital injection from IFC strengthens the balance sheet while management targets EBITDA breakeven by Q4 2026. Analyst consensus remains bullish with $12 price target despite recent earnings misses.
JMIA presents a turnaround story with operational improvements and path to profitability, but carries significant execution risk. The stock offers substantial upside to analyst targets if the company achieves its breakeven timeline, though persistent losses and competitive pressures remain concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
